Organism ID | Organism Name | Taxonomy Level | Family | SuperKingdom | Isolation Part | Collection Location | Collection Time | Reference |
---|---|---|---|---|---|---|---|---|
NPO1797 | Homo sapiens | Species | Hominidae | Eukaryota | DOI[10.1038/nbt.2488] | |||
NPO1797 | Homo sapiens | Species | Hominidae | Eukaryota | blood |
PMID[7877593] |
||
NPO20338 | Mus musculus | Species | Muridae | Eukaryota |
PMID[19425150] |
|||
NPO730 | Escherichia coli | Species | Enterobacteriaceae | Bacteria |
PMID[21988831] |
Target ID | Target Type | Target Name | Target Organism | Activity Type | Activity Relation | Value | Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPT26 | Individual Protein | Reverse transcriptase | Human immunodeficiency virus 1 | Kd | = | 1140 | nM | 17967907 |
NPT2 | Others | Unspecified | Kd | = | 2490 | nM | 17967907 | |
NPT2 | Others | Unspecified | Kd | = | 1230 | nM | 17967907 | |
NPT2 | Others | Unspecified | Kd | = | 2990 | nM | 17967907 | |
NPT2 | Others | Unspecified | Kd | = | 2510 | nM | 17967907 | |
NPT26 | Individual Protein | Reverse transcriptase | Human immunodeficiency virus 1 | Ratio | = | 1.07 | 17967907 | |
NPT2 | Others | Unspecified | Ratio | = | 0.53 | 17967907 | ||
NPT2 | Others | Unspecified | Ratio | = | 1.06 | 17967907 | ||
NPT2 | Others | Unspecified | Ratio | = | 0.44 | 17967907 | ||
NPT2 | Others | Unspecified | Ratio | = | 0.58 | 17967907 | ||
NPT26 | Individual Protein | Reverse transcriptase | Human immunodeficiency virus 1 | Activity | = | 1.2 | /s | 19596885 |
NPT26 | Individual Protein | Reverse transcriptase | Human immunodeficiency virus 1 | Kd | = | 1100 | nM | 19596885 |
NPT26 | Individual Protein | Reverse transcriptase | Human immunodeficiency virus 1 | Ratio | = | 1.1 | /uM/s | 19596885 |
NPT4216 | Individual Protein | Thymidine kinase, cytosolic | Cricetulus griseus | Inhibition | = | 27 | % | 458818 |
NPT1755 | Individual Protein | Thymidine kinase, cytosolic | Homo sapiens | Inhibition | = | 15 | % | 458818 |
NPT4863 | Individual Protein | Thymidine kinase, mitochondrial | Homo sapiens | Inhibition | = | 82 | % | 458818 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC329384 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
0.9663 | High Similarity | NPC328779 |
0.9551 | High Similarity | NPC120887 |
0.9451 | High Similarity | NPC328914 |
0.9438 | High Similarity | NPC6166 |
0.9438 | High Similarity | NPC226769 |
0.9438 | High Similarity | NPC280946 |
0.9121 | High Similarity | NPC90240 |
0.8953 | High Similarity | NPC229249 |
0.8652 | High Similarity | NPC190334 |
0.8652 | High Similarity | NPC62927 |
0.8085 | Intermediate Similarity | NPC322594 |
0.8085 | Intermediate Similarity | NPC320249 |
0.7979 | Intermediate Similarity | NPC324390 |
0.7835 | Intermediate Similarity | NPC283698 |
0.7835 | Intermediate Similarity | NPC73765 |
0.7766 | Intermediate Similarity | NPC328806 |
0.7732 | Intermediate Similarity | NPC36985 |
0.7732 | Intermediate Similarity | NPC17892 |
0.7374 | Intermediate Similarity | NPC324516 |
0.7374 | Intermediate Similarity | NPC318166 |
0.7264 | Intermediate Similarity | NPC329277 |
0.7234 | Intermediate Similarity | NPC106780 |
0.7172 | Intermediate Similarity | NPC327344 |
0.713 | Intermediate Similarity | NPC155087 |
0.713 | Intermediate Similarity | NPC149843 |
0.7129 | Intermediate Similarity | NPC317639 |
0.701 | Intermediate Similarity | NPC43246 |
0.701 | Intermediate Similarity | NPC89051 |
0.6911 | Remote Similarity | NPC318142 |
0.6907 | Remote Similarity | NPC325723 |
0.6813 | Remote Similarity | NPC315806 |
0.68 | Remote Similarity | NPC315063 |
0.6696 | Remote Similarity | NPC313813 |
0.6489 | Remote Similarity | NPC469972 |
0.6465 | Remote Similarity | NPC71339 |
0.6465 | Remote Similarity | NPC112842 |
0.6311 | Remote Similarity | NPC171116 |
0.6275 | Remote Similarity | NPC163352 |
0.6275 | Remote Similarity | NPC210456 |
0.626 | Remote Similarity | NPC284651 |
0.6186 | Remote Similarity | NPC325902 |
0.6082 | Remote Similarity | NPC329077 |
0.576 | Remote Similarity | NPC245534 |
0.5683 | Remote Similarity | NPC317746 |
0.5643 | Remote Similarity | NPC232408 |
0.5643 | Remote Similarity | NPC64705 |
0.5631 | Remote Similarity | NPC319753 |
0.5612 | Remote Similarity | NPC318590 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC329384 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
0.9451 | High Similarity | NPD1455 | Phase 3 |
0.9451 | High Similarity | NPD1454 | Phase 3 |
0.8953 | High Similarity | NPD9601 | Approved |
0.8763 | High Similarity | NPD6946 | Approved |
0.8652 | High Similarity | NPD9603 | Phase 3 |
0.8652 | High Similarity | NPD9602 | Phase 3 |
0.8652 | High Similarity | NPD9604 | Approved |
0.8605 | High Similarity | NPD9600 | Approved |
0.8556 | High Similarity | NPD9553 | Approved |
0.8556 | High Similarity | NPD9554 | Approved |
0.8409 | Intermediate Similarity | NPD9572 | Clinical (unspecified phase) |
0.837 | Intermediate Similarity | NPD267 | Discontinued |
0.8352 | Intermediate Similarity | NPD301 | Discontinued |
0.8295 | Intermediate Similarity | NPD9573 | Phase 2 |
0.828 | Intermediate Similarity | NPD9585 | Discontinued |
0.819 | Intermediate Similarity | NPD3138 | Phase 3 |
0.8113 | Intermediate Similarity | NPD3139 | Phase 3 |
0.8105 | Intermediate Similarity | NPD215 | Discontinued |
0.8022 | Intermediate Similarity | NPD9555 | Phase 2 |
0.7938 | Intermediate Similarity | NPD514 | Clinical (unspecified phase) |
0.7895 | Intermediate Similarity | NPD6943 | Clinical (unspecified phase) |
0.7835 | Intermediate Similarity | NPD9639 | Clinical (unspecified phase) |
0.7778 | Intermediate Similarity | NPD192 | Phase 2 |
0.7653 | Intermediate Similarity | NPD6948 | Phase 3 |
0.7556 | Intermediate Similarity | NPD9427 | Approved |
0.7429 | Intermediate Similarity | NPD1428 | Phase 2 |
0.7426 | Intermediate Similarity | NPD3121 | Phase 2 |
0.7333 | Intermediate Similarity | NPD3128 | Phase 3 |
0.7273 | Intermediate Similarity | NPD9405 | Approved |
0.7264 | Intermediate Similarity | NPD3129 | Phase 3 |
0.7238 | Intermediate Similarity | NPD4743 | Phase 2 |
0.7212 | Intermediate Similarity | NPD7651 | Approved |
0.7174 | Intermediate Similarity | NPD9403 | Discontinued |
0.7172 | Intermediate Similarity | NPD285 | Discontinued |
0.7156 | Intermediate Similarity | NPD1805 | Phase 2 |
0.7156 | Intermediate Similarity | NPD1804 | Phase 2 |
0.7083 | Intermediate Similarity | NPD9557 | Clinical (unspecified phase) |
0.7075 | Intermediate Similarity | NPD2633 | Phase 1 |
0.7059 | Intermediate Similarity | NPD762 | Discontinued |
0.7033 | Intermediate Similarity | NPD9407 | Approved |
0.701 | Intermediate Similarity | NPD9581 | Clinical (unspecified phase) |
0.701 | Intermediate Similarity | NPD9580 | Clinical (unspecified phase) |
0.6923 | Remote Similarity | NPD5789 | Clinical (unspecified phase) |
0.6863 | Remote Similarity | NPD1706 | Clinical (unspecified phase) |
0.6818 | Remote Similarity | NPD6693 | Phase 3 |
0.6813 | Remote Similarity | NPD9653 | Clinical (unspecified phase) |
0.6783 | Remote Similarity | NPD6935 | Phase 3 |
0.6783 | Remote Similarity | NPD6936 | Clinical (unspecified phase) |
0.6737 | Remote Similarity | NPD9429 | Discontinued |
0.6724 | Remote Similarity | NPD6918 | Phase 1 |
0.6667 | Remote Similarity | NPD1061 | Clinical (unspecified phase) |
0.6667 | Remote Similarity | NPD9556 | Approved |
0.66 | Remote Similarity | NPD1760 | Approved |
0.6598 | Remote Similarity | NPD9561 | Approved |
0.6598 | Remote Similarity | NPD9560 | Approved |
0.6598 | Remote Similarity | NPD2691 | Clinical (unspecified phase) |
0.6571 | Remote Similarity | NPD2621 | Clinical (unspecified phase) |
0.6569 | Remote Similarity | NPD9565 | Discontinued |
0.6531 | Remote Similarity | NPD9559 | Phase 1 |
0.6531 | Remote Similarity | NPD9546 | Phase 2 |
0.6526 | Remote Similarity | NPD9372 | Phase 2 |
0.6489 | Remote Similarity | NPD9370 | Approved |
0.6465 | Remote Similarity | NPD9533 | Phase 2 |
0.6465 | Remote Similarity | NPD280 | Approved |
0.6442 | Remote Similarity | NPD1686 | Approved |
0.6364 | Remote Similarity | NPD244 | Clinical (unspecified phase) |
0.6337 | Remote Similarity | NPD170 | Approved |
0.6337 | Remote Similarity | NPD9562 | Discovery |
0.6337 | Remote Similarity | NPD240 | Phase 3 |
0.6311 | Remote Similarity | NPD841 | Approved |
0.6226 | Remote Similarity | NPD501 | Phase 1 |
0.62 | Remote Similarity | NPD9529 | Phase 1 |
0.6162 | Remote Similarity | NPD9558 | Phase 3 |
0.6161 | Remote Similarity | NPD3161 | Clinical (unspecified phase) |
0.6154 | Remote Similarity | NPD7914 | Suspended |
0.6154 | Remote Similarity | NPD755 | Phase 3 |
0.6139 | Remote Similarity | NPD239 | Phase 2 |
0.6139 | Remote Similarity | NPD238 | Clinical (unspecified phase) |
0.6132 | Remote Similarity | NPD279 | Clinical (unspecified phase) |
0.6122 | Remote Similarity | NPD9369 | Clinical (unspecified phase) |
0.61 | Remote Similarity | NPD9535 | Phase 2 |
0.61 | Remote Similarity | NPD9534 | Phase 2 |
0.6091 | Remote Similarity | NPD223 | Clinical (unspecified phase) |
0.6055 | Remote Similarity | NPD502 | Approved |
0.5962 | Remote Similarity | NPD241 | Discontinued |
0.5938 | Remote Similarity | NPD9347 | Approved |
0.5938 | Remote Similarity | NPD9346 | Approved |
0.5897 | Remote Similarity | NPD284 | Phase 1 |
0.5888 | Remote Similarity | NPD251 | Approved |
0.5852 | Remote Similarity | NPD7761 | Suspended |
0.5776 | Remote Similarity | NPD1385 | Discontinued |
0.5772 | Remote Similarity | NPD7756 | Clinical (unspecified phase) |
0.5619 | Remote Similarity | NPD9654 | Phase 2 |
PubChem CID   | 65091 |
ChEMBL   | CHEMBL560403 |
ZINC   |
Molecular Weight:   | 466.99 |
ALogP:   | -2.661 |
MLogP:   | 0.36 |
XLogP:   | -4.121 |
# Rotatable Bonds:   | 14 |
Polar Surface Area:   | 278.39 |
# H-Bond Aceptor:   | 16 |
# H-Bond Donor:   | 7 |
# Rings:   | 2 |
# Heavy Atoms:   | 28 |